Akston Biosciences Collaborates with Purdue University to Co-Develop Immunotherapy for Cancer Treatment in Dogs
Shots:
- Akston Biosciences & Prude University have collaborated to co-develop an anti-cPD-L1 mAb immunotx. for cancer treatment in dogs. Akston gains exclusive option to license the therapy and will work as a CDMO for further development & production
- The study, expected to begin in H2’24, will assess safety, PK & antitumor effects of the mAb in companion dogs with bladder cancer at Purdue University. Parallel trials will also be carried out to find its effects on the anti-tumor immune responses
- The mAb will be supplied by Akston for the same. In addition, the trial will be supported by a grant from National Cancer Institute & the Werling Comparative Oncology Research Center at Purdue
Ref: Purdue University | Image: Akston Biosciences
Related News:- Can-Fite Reports Data from its Partner Vetbiolix’s Clinical Study of Piclidenoson in Dogs with Osteoarthritis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
